Can Wellbutrin (bupropion) be added to Pristiq (desvenlafaxine) 50mg for a patient with depression, who has shown no significant improvement after 6 weeks, and is also experiencing rumination and sexual dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Adding Wellbutrin (Bupropion) to Pristiq for Treatment-Resistant Depression with Sexual Dysfunction

Yes, adding bupropion to desvenlafaxine 50 mg is a clinically appropriate strategy at 6 weeks without adequate response, particularly given the patient's sexual dysfunction and rumination symptoms.

Rationale for Treatment Modification

At 6 weeks, this patient meets criteria for treatment modification. The American College of Physicians strongly recommends that clinicians modify treatment if patients do not have an adequate response to pharmacotherapy within 6 to 8 weeks of initiation 1. The response rate to initial antidepressant therapy may be as low as 50%, and approximately 38% of patients do not achieve treatment response during 6-12 weeks of treatment with second-generation antidepressants 1.

Why Bupropion Addition is Particularly Appropriate Here

Addressing Sexual Dysfunction

Bupropion has a significantly lower rate of sexual adverse events compared to SSRIs and SNRIs 1. This is critical because:

  • Desvenlafaxine (Pristiq), as an SNRI, commonly causes sexual dysfunction 1
  • Bupropion is associated with significantly lower rates of sexual adverse events than fluoxetine or sertraline 1
  • In controlled trials, bupropion effectively reverses antidepressant-associated sexual dysfunction when added to SSRIs or SNRIs 2
  • A Cochrane review found that adding bupropion 150 mg twice daily (not once daily) demonstrated benefit over placebo for sexual dysfunction (SMD 1.60,95% CI 1.40 to 1.81) 3

Augmentation Strategy Evidence

Open-label studies support that combination treatment with bupropion and an SSRI or SNRI is effective for treatment-resistant MDD 2. The combination is generally well tolerated, can boost antidepressant response, and can reduce SSRI/SNRI-associated sexual side effects 2.

Practical Implementation

Dosing Strategy

  • Start bupropion SR 150 mg once daily for 3-4 days, then increase to 150 mg twice daily 3, 4
  • The twice-daily dosing (total 300 mg/day) is more effective for sexual dysfunction than once-daily dosing 3
  • Maximum dose can reach 400 mg/day if needed for depression response 5
  • Continue the desvenlafaxine 50 mg unchanged initially 2

Consider Dose Optimization of Pristiq First

Before adding bupropion, evaluate whether increasing desvenlafaxine from 50 mg to 100 mg might be appropriate, as 50 mg is the starting dose. However, given the sexual dysfunction already present, adding bupropion rather than increasing the SNRI dose is the more strategic choice 1.

Safety Considerations

Drug Interactions

Bupropion is a CYP2D6 inhibitor, which could theoretically increase desvenlafaxine levels 6. However, this combination is used clinically and is generally well tolerated 2.

Monitoring Requirements

  • Assess for seizure risk factors - bupropion may be associated with increased seizure risk, particularly at doses above 450 mg/day 1
  • Monitor blood pressure - both desvenlafaxine and bupropion can increase blood pressure 1
  • Continue regular monitoring for suicidal ideation, particularly important during treatment changes 1
  • Reassess response at 2-4 weeks after bupropion addition 2

Alternative Consideration: Switching vs. Augmentation

While the evidence supports augmentation, one trial found that switching from sertraline to nefazodone reduced sexual dysfunction (RR 0.34,95% CI 0.19 to 0.60) 3. However, nefazodone is no longer clinically available, and there is an absence of randomized trials assessing switching to currently-available antidepressants with lower sexual side effect profiles 3. Given this evidence gap and the patient's partial response (implied by lack of "major" improvement rather than complete non-response), augmentation with bupropion is the more evidence-based approach than switching 2.

Expected Outcomes

  • Sexual function improvement: Should be evident within 2-4 weeks of adequate bupropion dosing 3, 2
  • Antidepressant response: May take 4-8 weeks to fully assess augmentation benefit 2
  • Rumination: While not specifically studied, improved overall depression response may reduce rumination symptoms 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.